 Home > Active Ingredient News > Antitumor Therapy > Aprea's Eprenetapopt has not yet reached the primary endpoint of treating TP53 mutant bone marrow growth syndrome

Aprea's Eprenetapopt has not yet reached the primary endpoint of treating TP53 mutant bone marrow growth syndrome

 Last Update: 2021-01-01
 Source: Internet
 Author: User

Tags

safety red

bone marrow protein

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Myelodysplastic syndromes (MDS) is a group of heterogeneic malignant hematopoietic stem cell diseases characterized by hematopoietic hyperplus, ineffective hematopoietics, and varying degrees of acute leukemia conversion risk.
have varying degrees of reduced production of red blood cells, plateplates, and mature granulocytes in patients with MDS, as well as functional defects, which often lead to anemia, bleeding, and an increased risk of infection.
Aprea Therapeutics announced Monday that its Phase III clinical trial evaluated the safety and ability of Eprenetapopt and Aza cytosine in the treatment of TP53 mutant bone marrow growth abnormal syndrome with a single-use azadide, but the results showed that the combined treatment group failed to reach the primary endpoint of the full remission (CR) rate.
company said that patients in the eprenetapoptosine treatment group had a 53 percent higher CR rate than those who used only azat, but that "no statistical difference was achieved."
, chief medical officer of Aprea Therapeutics, said: "While we are disappointed with the top line results, we remain confident that eprenetapopt can provide clinical benefits for patients with TP53 mutant malignancies."
。

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.